- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MEDESIS PHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 202,00 | +0,20 % | 7 Jahre USA, 10 Jahre EU: Warum Biogen, Novartis und NurExone auf den Orphan-Drug-Pfad setzen | ||
| ILLUMINA | 248,50 | +0,08 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| NANOREPRO | 1,780 | +2,30 % | NanoRepro gains majority in Deutsche Kosmetikwerke: NanoRepro gains majority in Deutsche Kosmetikwerke ... | On Wednesday, NanoRepro announced that it has gained the majority in Deutsche Kosmetikwerke (DKW) with its skincare brand newkee, to be consolidated from October '26 onwards. In detail: Bringing active... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,215 | 0,00 % | Wer hat die Formel für die Abnehmspritze 2.0? Überholen BioNxt Solutions und Merck jetzt Novo Nordisk und Eli Lilly? Was macht BioNTech? | Der Boom bei Medikamenten gegen Übergewicht schafft innerhalb der Pharmabranche einen Milliardenmarkt mit einem Volumen von 100 Mrd. USD jährlich. Novo Nordisk und Eli Lilly kämpfen hier um die Vorherrschaft.... ► Artikel lesen | |
| CYTODYN | 0,170 | 0,00 % | CytoDyn Inc.: CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026 | ||
| IMMUNIC | 7,368 | +0,63 % | EQS-News: Immunic AG: Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 23,280 | -1,52 % | Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure | SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune... ► Artikel lesen | |
| GENPREX | 2,725 | +0,18 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| PERSONALIS | 14,130 | -1,12 % | Personalis, Inc. - 8-K, Current Report | ||
| VITROLIFE | 8,580 | +0,29 % | Vitrolife AB: Vitrolife Group appoints Erin Schardt Senior Vice President and General Manager, Americas. She will join the Executive Management Team. | Vitrolife Group today announced the appointment of Erin Schardt as Senior Vice President and General Manager, Americas, effective immediately. In this expanded role, Erin will assume responsibility... ► Artikel lesen | |
| PLURI | 4,660 | -100,00 % | Pluri Inc. - S-1, General form for registration of securities | ||
| LEGEND BIOTECH | 16,700 | +0,60 % | Legend Biotech Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| ADOCIA | 2,044 | 0,00 % | Number of Shares and Voting Rights of ADOCIA as of September 30, 2026 | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen | |
| OSE IMMUNOTHERAPEUTICS | 2,134 | 0,00 % | OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update | €11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026The Company continues to engage actively with institutional investors in the United States and Europe to... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,475 | +1,72 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen |
Das Unternehmen MEDESIS PHARMA SA kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDESIS PHARMA SA finden Sie auf Wallstreet Online.